Nour Al-Mozain: Why Stem Cell Collection Parameters Need Adjustment in SCD for Gene Therapy?
Nour Al-Mozain, Hemopathologist, Consultant at King Faisal Specialist Hospital and Research Center, shared a post on LinkedIn about a recent article by Yvette C Tanhehco et al., published in Blood Advances, adding:
“Stay Steady. Establish the Interface
Why do we need to adjust the standard parameters when collecting stem cells from SCD patients for gene therapy?
- Activated platelets and leukocytes promote aggregation and interface disruption
- Increased blood viscosity causes impaired component separation
- Abnormal RBC morphology leads to altered sedimentation dynamics
SCD blood exhibits elevated viscous resistance and abnormal flow behavior, even outside crisis states which leads to unstable interface and lower collection efficiency.
Performing RBC exchange immediately before collection may transiently reduce cellular activation.
Adjusting machine configuration by:
Increasing packing factor (centrifugal force) to compensate for increased viscosity
Collecting deeper within the buffy coat (accepting higher product Hct) improves CD34 and CE.”
Title: Challenges and limitations of mobilization and stem cell collection for gene therapy of sickle cell disease
Authors: Yvette C Tanhehco , Suzanne Thibodeaux , Patricia A Shi , Stella T Chou , Shannon A Kelly , Grace Fortes Monis , Carly Newton , Kamille West-Mitchell , Yan Zheng , Christine Fernandez , Christina Anderson , Kimberly Ching , Victoria Coleman-Cowger , Adrienne Shapiro , John P Manis
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 3, 2026, 17:18Giacomo Rossi: Cysteine and Gut Health – MIT Finds the Switch
-
Jun 3, 2026, 17:00Amin Ullah: Presence of RBCs of Unequal Sizes in a Peripheral Blood Smear – Anisocytosis of RBC
-
Jun 3, 2026, 16:59Jean Connors: Discussing Cancer-Associated Thrombosis at the Japanese Society of Thrombosis and Hemostasis
-
Jun 3, 2026, 16:54Ayush Bhowmik: Failed Drug Became the World’s Most Widely Used Blood Thinner
-
Jun 3, 2026, 16:13Salvador Payán Pernía: Arguing against a Significant Role for Erythropoietin Analogues in the Management of PRCA
-
Jun 3, 2026, 16:08Pedro Henrique Las Casas: How Anticoagulant Agents and Quercetin Influence Cancer Cell Procoagulant Activity
-
Jun 3, 2026, 16:07Suraj Wilson: Back From ASCO 2026 With A Renewed Commitment To Cancer Research
-
Jun 3, 2026, 16:06Kerin A. Da Cruz: MSTU Team Is Creating The Future of Stroke Care In the Northeast Florida
-
Jun 3, 2026, 16:06Andrew Lee: Examining Rare Clotting Disorders After Adenovirus-Based COVID-19 Vaccination